Boston Scientific announces positive FRACTURE trial results for SEISMIQ catheter
The SEISMIQ 4CE catheter met primary safety and effectiveness endpoints for treating severe coronary artery disease.
See the latest news and media coverage for Boston Scientific. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global medical device manufacturer
bostonscientific.comLast updated
In short: Boston Scientific reported strong Q1 2026 growth, made a major $1.5 billion investment in MiRus, and faced legal and regulatory challenges.
The SEISMIQ 4CE catheter met primary safety and effectiveness endpoints for treating severe coronary artery disease.
The ASR with JPMorgan will repurchase 80% of the $2 billion upfront, settled by June 2026, accretive to EPS.
The investment includes an exclusive option to acquire a novel TAVR system using rhenium alloy.
Data from AVANT GUARD trial shows FARAPULSE PFA superiority over anti-arrhythmic drugs. WATCHMAN LAAC devices demonstrate safety and effectiveness in multiple studies.
Renaissance Investment Management, an investment management company, released its Q1 2026 "Large Cap Growth Strategy." A copy of the letter can be downloaded here.
Penumbra received FDA clearance for its Thunderbolt stroke thrombectomy device. Boston Scientific...
BSX stock fell to an annual low of $45.99 last week after it received multiple price target cuts...
The U.S. Food and Drug Administration Tuesday warned of "serious regulatory problems" in medical devices shipped from a Boston Scientific distribution plant in Massachusetts. The...
Track Boston Scientific and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Boston Scientific and other trending companies.